|
Uridine-5'-Diphosphate-N-Acetylmuramoyl-L-Alanine-D-Glutamate
|
DB02314 |
|
|
2,3-di-O-phytanyl-sn-glycerol
|
DB03646 |
|
|
Cyclic GMP
|
DB02315 |
[Cyclic guanosine monophosphate (Cyclic GMP) is a guanine nucleotide containing one phosphate group which is esterified to the sugar moiety in both the 3'- and 5'-positions. It is a cellular regulatory agent and has been described as a second messenger. Its levels increase in response to a variety of hormones, including acetylcholine, insulin, and oxytocin and it has been found to activate specific protein kinases. (From Merck Index, 11th ed)] |
|
M40403
|
DB04976 |
[M40403 is a low molecular weight, synthetic manganese containing superoxide dismutase mimetic (SODm) that selectively removes superoxide anion.] |
|
Banoxantrone
|
DB04975 |
[Banoxantrone is a highly selective bioreductive drug that is activated in, and is preferentially toxic to, hypoxic cells in tumours. It has been shown to work synergistically with fractionated radiation to significantly delay growth of tumours compared to administration of either banoxantrone or radiation alone. Banoxantrone was also efficacious in tumour models when administered in combination with either cisplatin or chemoradiation. [A3115]] |
|
beta-D-galactose 6-phosphate
|
DB02312 |
|
|
CRA_1144
|
DB03643 |
|
|
3-hydroxyanthranilic acid
|
DB03644 |
[An oxidation product of tryptophan metabolism. It may be a free radical scavenger and a carcinogen.] |
|
Ethyl (4R)-4-{[(2R,5S)-2-(4-fluorobenzyl)-6-methyl-5-{[(5-methyl-1,2-oxazol-3-yl)carbonyl]amino}-4-oxoheptanoyl]amino}-5-[(3S)-2-oxo-3-pyrrolidinyl]pentanoate
|
DB02313 |
|
|
Rimiducid
|
DB04974 |
[Rimiducid is a lipid-permeable tacrolimus analogue and a protein dimerizer. It was designed to overcome limitations of current cellular immunotherapies used for cancer and other blood disorders by enhancing the control of the immune cell activity and function. When administered via chemically-inducible dimerization (CID) technologies, rimiducid binds to switch proteins and dimerizes them, triggering downstream signaling cascade.[A187496,L9521] The combination use of rimiducid with immunotherapies for enhanced therapeutic effectiveness is currently under investigation.] |
|
LErafAON
|
DB04973 |
[NeoPharm is developing liposome-encapsulated, c-Raf antisense oligodeoxynucleotides (LErafAON) for the potential treatment of various solid tumors, including those that have become resistant to radiation or chemotherapy. Phase I/II trials commenced in March 2001 and were ongoing as of June 2003.] |
|
3,5,6,8-Tetramethyl-N-Methyl Phenanthrolinium
|
DB02310 |
|
|
2'-deoxyuridine 5'-alpha,beta-imido-diphosphate
|
DB03641 |
|
|
Methyl Methylsulfinylmethyl Sulfide
|
DB02311 |
|
|
N-[(2S)-4-Methyl-1-oxo-1-{[(4S)-3-oxo-1-(2-pyridinylsulfonyl)-4-azepanyl]amino}-2-pentanyl]-1-benzofuran-2-carboxamide
|
DB03642 |
|
|
Canfosfamide
|
DB04972 |
[Canfosfamide is an active agent in chemotherapy-resistant ovarian cancer.] |
|
Reglitazar
|
DB04971 |
[Reglitazar, an isoxazolidine-3,5-dione derivative, is being developed by Pfizer for the treatment of diabetes. It is the first non-thiazolidenedione to enter clinical trials.] |
|
Beta-Hydroxyaspartic Acid
|
DB03640 |
|
|
Lesopitron
|
DB04970 |
[Lesopitron is an anxiolytic with pre- and post-synaptic 5-HT1A agonist activity, which is under development by Esteve.] |
|
Lemuteporfin
|
DB04980 |
[Lemuteporfin, under development by QLT Incorporated, is a benzoporphyrin-derived chlorin-like photosensitizer. It is intended for the treatment of beign prostatic hyperplasia.] |
